• FBXO22 Recruitment Ligands for Targeted Protein Degradation

  2026-09-17

  This 2025 preprint identifies chemical probes that either degrade FBXO22 or use it as an E3-ligase recruiter for targeted protein degradation. Its key advances are the potent FBXO22 degrader AHPC(Me)-C6-NH2, the discovery of hexane-1,6-diamine as a minimal self-degrader, and the use of 2-pyridinecarboxaldehyde as a reversible cysteine-reactive recruitment element.

• Esflurbiprofen and Fast-Onset Antidepressant Mechanisms

  2026-09-17

  The reference study identifies disruption of the SERT–nNOS complex in the dorsal raphe nucleus as a strategy for accelerating antidepressant responses, and uses mBRET screening, stress models, and resting-state fMRI to evaluate esflurbiprofen. Its findings connect molecular target engagement with serotonergic circuit activity and behavior, while also defining important limits for translation beyond mouse models.

• Ferrostatin-1 and Membrane Injury Biology

  2026-09-16

  Ferrostatin-1 (Fer-1) is best understood not only as a ferroptosis blocker, but also as a causal probe for separating oxidative lipid damage from acute plasma-membrane injury. This article connects Fer-1 assay design with new insights from Kupffer-cell membrane repair research.

• Griseofulvin in Reliable Microtubule Assays

  2026-09-16

  This scenario-based guide explains how Griseofulvin, SKU B3680, can support mechanism-focused viability, proliferation, and cytotoxicity workflows. It covers DMSO handling, exposure design, multiparametric interpretation, and evidence-based product selection without overstating what current literature has validated.

• Griseofulvin: Mapping Microtubule Mechanisms

  2026-09-15

  Griseofulvin is more than a conventional antifungal research reagent: it is a mechanistic probe for connecting fungal cell mitosis, microtubule dynamics, and aneugenicity assessment. This translational perspective combines assay evidence with practical guidance for positioning Griseofulvin in modern antifungal drug research.

• GKT137831 for Reliable Redox Cell Assays

  2026-09-15

  Learn how GKT137831, SKU B4763, can help researchers separate Nox1/Nox4-driven oxidative signaling from nonspecific assay artifacts. This scenario-based guide covers formulation, dose selection, ROS and viability readouts, ferroptosis interpretation, and practical supplier evaluation.

• MK-0812: Mapping Gut–Liver Immune Causality

  2026-09-14

  MK-0812 enables targeted investigation of CCR2-dependent monocyte trafficking in gut–liver inflammation. This article presents a causal assay framework that separates intestinal disease initiation from hepatic immune amplification in MASH research.

• Vidarabine Monohydrate: Assay Design Guide

  2026-09-14

  Vidarabine monohydrate is an adenosine-mimetic antiviral research compound for studying viral DNA synthesis and replication. This guide focuses on assay architecture, DMSO handling, orthogonal validation, and how to avoid overinterpreting antiviral readouts.

• Mithramycin A Workflows for Transcription Studies

  2026-09-13

  Mithramycin A is a G-C-rich DNA-binding anticancer antibiotic for testing transcription-dependent phenotypes, from c-myc regulation and myeloid differentiation to exploratory cardiac stress models. This workflow emphasizes controlled exposure, orthogonal readouts, and clear limits when translating cancer biology tools into doxorubicin-induced heart failure research.

• TEAD2 Links HCC Prognosis to Ferroptosis

  2026-09-12

  Ren et al. combined public-database analysis with in vitro validation to identify TEAD2 as a prognostic factor and potential ferroptosis regulator in hepatocellular carcinoma. The study connects TEAD2 loss with iron accumulation, oxidative damage, and HCC cell death, while also associating TEAD expression with tumor immune infiltration.

• FTSJ3 Loss, R-Loops, and Lung Cancer Chemosensitivity

  2026-09-11

  The reference study identifies FTSJ3 as a regulator of R-loop homeostasis and genomic stability in lung cancer cells. Its loss increases R-loop-associated DNA damage and enhances cisplatin sensitivity, supporting FTSJ3 as a potential biomarker of chemotherapy response while clarifying an important connection between RNA–DNA structures and cancer treatment.

• HRP Goat Anti-Rabbit IgG (H+L) Antibody Guide

  2026-09-11

  This HRP-conjugated secondary antibody supports detection of rabbit IgG primary antibodies in Western blotting, ELISA, IHC, and IC workflows. It is for research use only, with no diagnostic or medical application, and assay-specific dilution and incubation conditions require local validation.

• 2'3'-cGAMP: A Practical STING Assay Workflow

  2026-09-10

  Build a controlled STING activation workflow that separates direct pathway competence from upstream mitochondrial DNA sensing. This article combines 2'3'-cGAMP benchmarking with NAD-depletion models, practical assay parameters, and troubleshooting for innate immunity and immunotherapy research.

• Ferrostatin-1 in GPX4 Ferroptosis Assays

  2026-09-10

  Ferrostatin-1 (Fer-1) is more than a ferroptosis inhibitor: it is a causal control for connecting GPX4, lipid peroxidation, and treatment resistance. This article translates prostate cancer findings into practical assay design and interpretation.

• Sitagliptin Phosphate Monohydrate in Gut–Glucose Research

  2026-09-09

  Use Sitagliptin phosphate monohydrate to separate DPP-4-dependent incretin biology from intestinal stretch signals that regulate feeding and glucose tolerance. This workflow combines enzyme assays, cell models, and carefully controlled metabolic challenges for more interpretable type II diabetes treatment research.

8093 records 1/540 page Next 12345 下5页 Last page